CoChat

Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure

Open access
Karvellas, Constantine J., Speiser, Jaime L., Tremblay, Mélanie, Lee, William M., Rose, Christopher F., for the US Acute Liver Failure Study Group · 2017 · Hepatology
Cited by 71

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Acetaminophen (APAP)‐induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver‐type fatty acid binding protein (FABP1) early (day 1) or late (day 3‐5) levels are associated with 21‐day mortality in the absence of liver transplant. Serum samples from 198 APAP‐ALF patients (nested case–control study with 99 survivors, 99 nonsurvivors) were analyzed by enzyme‐linked immunosorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998‐2014). APAP‐ALF survivors had significantly lower serum FABP1 levels early (238.6 versus 690.8 ng/mL, P < 0.0001) and late (148.4 versus 612.3 ng/mL, P < 0.0001) compared with nonsurvivors. FABP1 > 350 ng/mL was associated with significantly higher risk of death at early (P = 0.0004) and late (P < 0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio = 1.31, P = 0.027) and late (log FABP1 odds ratio = 1.50, P = 0.005) were associated with significantly increased 21‐day mortality after adjusting for significant covariates (Model for End‐Stage Liver Disease, vasopressor use). Areas under the receiver operating characteristic curve for early and late multivariable models were 0.778 and 0.907, respectively. The area under the receiver operating characteristic curve of the King's College criteria (early, 0.552 alone, 0.711 with FABP1; late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766 with FABP1; late, 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (P < 0.002 for all). Conclusion: In patients with APAP‐ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice; validation of FABP1 as a clinical prediction tool in APAP‐ALF warrants further investigation. (H epatology 2017;65:938‐949)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.28945

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 71

Metadata

Authors
Karvellas, C. J., Speiser, J. L., Tremblay, M., Lee, W. M., Rose, C. F., & for the US Acute Liver Failure Study Group
Venue
Hepatology
Published
2017-01-19
Volume
65
Issue
3
Pages
938-949
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2549803295
Cited by
71
References
2
FWCI
5.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure. https://app.cochat.ai/papers/10.1002/hep.28945
The paper
Karvellas, C. J., Speiser, J. L., Tremblay, M., Lee, W. M., Rose, C. F., & for the US Acute Liver Failure Study Group. (2017). Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure. Hepatology. https://doi.org/10.1002/hep.28945

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.